林建廷

Cancer 2006;106:2657–63

55% 34% 5% OS 25%Ph+ Standard risk High risk All pts cHR pts Risk stratification at diagnosis

 Germany GMALL group Germany GMALL group ◦ rt-PCR method, 105 pts in cHR with MRD(-) at enroll ◦ No high WBC, not pro-B, pre-T, mature T, no poor cyt ◦ Median molecular to clinical relapse:9.5m Blood. 2007;109: /28 (61%) 5/77 (6%)

Haematologica 2008 Feb; 93(2):

 Retrospective, 97 pts Haematologica 2008 Feb; 93(2): yr Leukemic-free survival Non-relapse mortalityRelapse incidence 52% 42% 18% for CR1 for CR1

 HCT-CI is 0, and NRM~20% HCT-CI

Risk Groups LowCML in CP RA AA IntCML in AP CML BP then CP Acute leukemia in remission Lymphoma in remission RAEB CLL PNH HighCML in BP Acute leukemia in relapse Lymphoma in relapse RAEB-t Myeloma Solid cancer

CategoryScoreProbability of Death 19-16<25% % % >75%  PAM score is: PAM score ◦ 17 if RIST ◦ 20 if myeloablative (non-TBI) ◦ 24 if myeloablative (TBI 12 Gy)